Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 06:45 ETSource: Eli Lilly
From the source
Read at investor.lilly.comLilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
